A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

@article{Srivastava2018ASF,
  title={A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target},
  author={Prashant K. Srivastava and Jonathan van Eyll and Patrice Godard and Manuela Mazzuferi and Andr{\'e}e Delahaye-Duriez and Juliette Van Steenwinckel and Pierre Gressens and B{\'e}n{\'e}dicte Danis and Catherine Vandenplas and Patrik Foerch and Karine Leclercq and Georges Mairet-Coello and Alvaro Cardenas and Frederic Vanclef and Liisi Laaniste and Isabelle Niespodziany and James Keaney and Julien Gasser and Ga{\"e}lle Gillet and Kirill Shkura and Seon-Ah Chong and Jacques Behmoaras and Irena Kadiu and Enrico G Petretto and Rafal M. Kaminski and Michael R. Johnson},
  journal={Nature Communications},
  year={2018},
  volume={9}
}
The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning (“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for… Expand
A systems-level framework for anti-epilepsy drug discovery
TLDR
A new approach to the identification of novel disease modifying anti-epilepsy drugs is described, which aims to first identify pathophysiological mechanisms by integrating polygenic risk with cellular gene expression profiles and then to relate these molecular mechanisms to druggable targets using a gene regulatory (regulome) framework. Expand
A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy
TLDR
These studies reveal potential treatments for drug-resistant epilepsy and identify shared, dysregulated, and functionally active microRNAs during the pathogenesis of epilepsy which represent therapeutic antiseizure targets. Expand
Machine Learning techniques to identify potential drug targets for Anti-epileptic drugs
Epilepsy is a neurological disorder affecting millions worldwide. Though many Anti-epileptic drugs (AEDs) are available for treatment, almost 30% of patients with Epilepsy (PWE) are resistant toExpand
Temporal dynamics of a CSF1R signaling gene regulatory network involved in epilepsy
TLDR
In silico analysis of the GRN dynamics predicted that a pro-inflammatory stimulus can induce irreversible bistability whereby the expression level of GRN components occurs as two distinct states, providing a theoretical foundation to the need for chronic GRN control and the limited potential for disease modification via inhibition of CSF1R. Expand
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
  • Soo Youn Lee, Min-Young Song, +5 authors Young Hye Kim
  • Medicine
  • Frontiers in Pharmacology
  • 2019
TLDR
A proteotranscriptomic-based computational drug repositioning method based on inverse associations between disease- and drug-induced gene and protein perturbation patterns, incorporating pharmacogenomic knowledge is developed, suggesting a shortcut to discover new efficacy of drugs for AD. Expand
The path from scientific discovery to cures for epilepsy
TLDR
The progress in scientific discovery propelling the goal of developing and implementing cures for epilepsy is discussed, including identification of genetic risk factors and big data approaches that integrate clinical and molecular 'omics' datasets to identify common pathophysiological signatures and biomarkers. Expand
Systems-level analysis identifies key regulators driving epileptogenesis in temporal lobe epilepsy
TLDR
A systems-level analytic framework is built which integrates gene meta-signatures, gene coexpression network and cellular regulatory network to unveil the evolution landscape of epileptogenic process and to identify key regulators that govern the transition between different epileptogenesis stages. Expand
A Transcriptome‐Based Drug Discovery Paradigm for Neurodevelopmental Disorders
TLDR
This approach attempts to identify compounds that reverse gene‐expression signatures associated with disease states by applying a drug discovery approach originally developed for cancer called “transcriptome reversal” for these neurodevelopmental disorders. Expand
Establishing a transcriptome-based drug discovery paradigm for neurodevelopmental disorders
TLDR
This approach, originally developed for cancer, attempts to identify compounds that reverse gene-expression signatures associated with disease states and proposes the application of a drug discovery approach called “transcriptome reversal” for these disorders. Expand
Systems-level analysis identifies key regulators driving epileptogenesis in temporal lobe epilepsy.
TLDR
The upregulation of FAM107A, LAMB2, LTBP1 and TGIF1, which are mainly involved in nervous system development, were found contributing to both conditions and provide candidate regulators that may serve as potential antiepileptogenic targets. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment
TLDR
It is highlighted how systems genetics and gene network analyses have suggested that pathways disrupted in epilepsy overlap with those of other neurodevelopmental traits including human cognition and how network-based computational approaches are now being applied to epilepsy drug discovery. Expand
Discovery of drug mode of action and drug repositioning from transcriptional responses
TLDR
This work developed an automatic and robust approach that exploits similarity in gene expression profiles following drug treatment, across multiple cell lines and dosages, to predict similarities in drug effect and MoA, and correctly predicted the MoA for nine anticancer compounds and was able to discover an unreported effect for a well-known drug. Expand
Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery
TLDR
Functional disruption of M30 via gene mutation or altered expression as a convergent mechanism regulating susceptibility to epilepsy broadly is suggested. Expand
New avenues for anti-epileptic drug discovery and development
TLDR
It is proposed that future anti-epileptic drug development may be improved through a new joint endeavour between academia and the industry, through the identification and application of tools for new target-driven approaches, and through comparative preclinical proof-of-concept studies and innovative clinical trials designs. Expand
Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus.
TLDR
RNA sequencing analysis in a mouse model of TLE shows the proconvulsive module is preserved across-species, specific to the epileptic hippocampus and upregulated in chronic epilepsy, and it is demonstrated that SESN3 positively regulates the module in macrophages, microglia and neurons. Expand
Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis?
  • A. Vezzani
  • Medicine
  • Expert opinion on drug safety
  • 2015
TLDR
Clinical translation of anti-inflammatory intervention may take advantage of drugs already used in clinical practice for peripheral or other CNS disorders with a pathogenic neuroinflammatory component, to represent disease-modifying treatments. Expand
Intrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness
TLDR
It is suggested that neurobiological factors that confer increased disease severity lead to drug intractability, and the occurrence of frequent seizures at disease onset is an important factor that signals increased severity. Expand
A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions
TLDR
The refined signatures of paclitaxel response are validated by mining a large drug screening dataset, showing that human cancer cell lines whose basal transcriptional profile is anti-correlated to them are significantly more sensitive to pac litaxel and docetaxel. Expand
Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs
TLDR
Preclinical strategies of AED discovery and development need a conceptual shift that is moving away from using models that identify therapies for the symptomatic treatment of epilepsy to those that may be useful for identifying therapies that are more effective in the refractory population. Expand
Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks
TLDR
This work proposed a framework for the systematic discovery of genetic alterations that are causal determinants of disease, by prioritizing genes upstream of functional disease drivers, within regulatory networks inferred de novo from experimental data, and tested this framework by identifying the genetic determinant of the mesenchymal subtype of glioblastoma. Expand
...
1
2
3
4
5
...